Home Cart Sign in  
Chemical Structure| 289483-69-8 Chemical Structure| 289483-69-8

Structure of E7820
CAS No.: 289483-69-8

Chemical Structure| 289483-69-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

E7820 (ER68203-00) is an orally active aromatic sulfonamide derivative and a unique angiogenesis inhibitor that inhibits the expression of integrin alpha2 subunit on endothelial cells. E7820 inhibits rat aortic angiogenesis with an IC50 of 0.11 μg/ml. E7820 modulates the mRNA expression of α-1, α-2, α-3, and α-5 integrins. It possesses anti-angiogenic and anti-tumor activities.

Synonyms: ER68203-00

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of E7820

CAS No. :289483-69-8
Formula : C17H12N4O2S
M.W : 336.37
SMILES Code : O=S(C1=CC=CC(C#N)=C1)(NC2=CC=C(C)C3=C2NC=C3C#N)=O
Synonyms :
ER68203-00
MDL No. :MFCD09833234
InChI Key :LWGUASZLXHYWIV-UHFFFAOYSA-N
Pubchem ID :196970

Safety of E7820

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of E7820

cytoskeleton

Isoform Comparison

Biological Activity

Description
E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a unique angiogenesis inhibitor that suppresses the expression of the integrin alpha2 subunit on endothelial cells. It inhibits angiogenesis in rat aorta with an IC50 of 0.11 µg/ml and affects the expression of α-1, α-2, α-3, and α-5 integrin mRNA. E7820 displays antiangiogenic and antitumor activity[1][2].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05024994 Acute Myeloid Leukemia|Myelody... More >>splastic Syndromes|Chronic Myelomonocytic Leukemia Less << PHASE2 ACTIVE_NOT_RECRUITING 2025-08-25 University of Miami (Data Coll... More >>ection AND Specimen Analysis Only), Miami, Florida, 33136, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester (All protocol activities), Harrison, New York, 10604, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States Less <<
NCT00078637 Neoplasms|Lymphoma, Malignant PHASE1 COMPLETED 2025-02-07 San Antonio, Texas, United Sta... More >>tes Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.97mL

0.59mL

0.30mL

14.86mL

2.97mL

1.49mL

29.73mL

5.95mL

2.97mL

References

 

Historical Records

Categories